Allergic Rhinitis Due to Dust Mite
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BiocorpFrance - Issoire
1 program1
Sublingual Film for Dermatophagoides pteronyssinusPhase 21 trial
Active Trials
Stallergenes GreerFrance - Antony
1 program300 IR house dust mites allergen extract tabletPHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Stallergenes Greer300 IR house dust mites allergen extract tablet
BiocorpSublingual Film for Dermatophagoides pteronyssinus
Clinical Trials (2)
Total enrollment: 721 patients across 2 trials
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children
Start: Oct 2009Est. completion: Sep 2011471 patients
Phase 3Terminated
Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites
Start: Mar 2026Est. completion: Dec 2027250 patients
Phase 2Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.